173 related articles for article (PubMed ID: 37202499)
61. Glofitamab (Columvi) for diffuse large B-cell lymphoma.
Med Lett Drugs Ther; 2023 Aug; 65(1682):e129-e130. PubMed ID: 37516899
[No Abstract] [Full Text] [Related]
62. The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, Nice, France).
Bontoux C; Marcovich A; Goffinet S; Pesce F; Tanga V; Bohly D; Salah M; Washetine K; Messaoudi Z; Felix JM; Bonnetaud C; Wang L; Menon G; Berthet JP; Cohen C; Benzaquen J; Marquette CH; Lassalle S; Long-Mira E; Hofman V; Xerri L; Ilié M; Hofman P
J Pers Med; 2023 Jun; 13(7):. PubMed ID: 37511690
[TBL] [Abstract][Full Text] [Related]
63. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.
Hassan R; Butler M; O'Cearbhaill RE; Oh DY; Johnson M; Zikaras K; Smalley M; Ross M; Tanyi JL; Ghafoor A; Shah NN; Saboury B; Cao L; Quintás-Cardama A; Hong D
Nat Med; 2023 Aug; 29(8):2099-2109. PubMed ID: 37501016
[TBL] [Abstract][Full Text] [Related]
64. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
Gini G; Tani M; Tucci A; Marcheselli L; Cesaretti M; Bellei M; Pascarella A; Ballerini F; Petrini M; Merli F; Olivieri A; Lanza F; Annibali O; Zilioli VR; Liberati AM; Tisi MC; Arcari A; Marino D; Musuraca G; Pavone V; Fabbri A; Pozzi S; Mannina D; Plenteda C; Celli M; Luminari S
Blood; 2023 Oct; 142(17):1438-1447. PubMed ID: 37418685
[TBL] [Abstract][Full Text] [Related]
65. Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis.
Qiao L; Liu Q; Huang C
Medicine (Baltimore); 2023 Jul; 102(27):e33880. PubMed ID: 37417642
[TBL] [Abstract][Full Text] [Related]
66. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR; Oluwole OO; Kersten MJ; Miklos DB; Perales MA; Ghobadi A; Rapoport AP; Sureda A; Jacobson CA; Farooq U; van Meerten T; Ulrickson M; Elsawy M; Leslie LA; Chaganti S; Dickinson M; Dorritie K; Reagan PM; McGuirk J; Song KW; Riedell PA; Minnema MC; Yang Y; Vardhanabhuti S; Filosto S; Cheng P; Shahani SA; Schupp M; To C; Locke FL; ;
N Engl J Med; 2023 Jul; 389(2):148-157. PubMed ID: 37272527
[TBL] [Abstract][Full Text] [Related]
67. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
Apollonio B; Spada F; Petrov N; Cozzetto D; Papazoglou D; Jarvis P; Kannambath S; Terranova-Barberio M; Amini RM; Enblad G; Graham C; Benjamin R; Phillips E; Ellis R; Nuamah R; Saqi M; Calado DP; Rosenquist R; Sutton LA; Salisbury J; Zacharioudakis G; Vardi A; Hagner PR; Gandhi AK; Bacac M; Claus C; Umana P; Jarrett RF; Klein C; Deutsch A; Ramsay AG
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37219943
[TBL] [Abstract][Full Text] [Related]
68. Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma.
Avenoso D; Alabdulwahab A; Kenyon M; Mehra V; Krishnamurthy P; Dazzi F; Leung YT; Anteh S; Shah MN; Kuhnl A; Sanderson R; Patten P; Yallop D; Pagliuca A; Potter V
Mediterr J Hematol Infect Dis; 2023; 15(1):e2023041. PubMed ID: 37435036
[TBL] [Abstract][Full Text] [Related]
69. Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.
Yang S; Li N; Zhu R; Feng Y; Zhuo J; Gale RP; Huang X
Ann Hematol; 2023 Aug; 102(8):2181-2188. PubMed ID: 37393401
[TBL] [Abstract][Full Text] [Related]
70. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
[No Abstract] [Full Text] [Related]
71. Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.
Ababneh HS; Ng AK; Frigault MJ; Abramson JS; Johnson PC; Jacobson CA; Patel CG
Haematologica; 2023 Nov; 108(11):2972-2981. PubMed ID: 37317884
[TBL] [Abstract][Full Text] [Related]
72. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).
Gumà J; Palazón-Carrión N; Rueda-Domínguez A; Sequero S; Calvo V; García-Arroyo R; Gómez-Codina J; Llanos M; Martínez-Banaclocha N; Provencio M
Clin Transl Oncol; 2023 Sep; 25(9):2749-2758. PubMed ID: 37289353
[TBL] [Abstract][Full Text] [Related]
73. Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome.
Qazi S; Uckun FM
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240940
[TBL] [Abstract][Full Text] [Related]
74. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
Armitage JO; Weisenburger DD
J Clin Oncol; 1998 Aug; 16(8):2780-95. PubMed ID: 9704731
[TBL] [Abstract][Full Text] [Related]
75. Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B; Chung E; Wellard C; Yoo E; Bennett R; Birks C; Johnston A; Cheah CY; Hamad N; Simpson J; Barraclough A; Ku M; Viiala N; Ratnasingam S; Armytage T; Cochrane T; Chong G; Lee D; Manos K; Keane C; Wallwork S; Opat S; Hawkes EA
EJHaem; 2024 Apr; 5(2):325-332. PubMed ID: 38633125
[TBL] [Abstract][Full Text] [Related]
76. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
[TBL] [Abstract][Full Text] [Related]
77. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
[TBL] [Abstract][Full Text] [Related]
78. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
79. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF
Ann Hematol; 2023 Jan; 102(1):133-140. PubMed ID: 36401621
[TBL] [Abstract][Full Text] [Related]
80. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
